Corcept Therapeutics Incorporated

Healthcare · Biotechnology

Overall research band Mixed

Quality Weak

Valuation Very weak

Balance sheet Exceptional

Market confirmation Exceptional

One-minute company read

What this report can tell you now

What the company does

Corcept Therapeutics Incorporated is a pharmaceutical company based in Menlo Park, California, focused on discovering, developing, and commercializing treatments for serious metabolic, oncological, and neuropsychiatric disorders in the United States. Its main product is Korlym (mifepristone) tablets, an oral medication prescribed for adult patients with endogenous Cushing's syndrome who have hyperglycemia due to hypercortisolism and for whom surgery has failed or is not an option. Corcept's development pipeline includes relacorilant for Cushing's syndrome and in combination with nab-paclitaxel for advanced ovarian tumors, as well as selective cortisol modulators for metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain. The company generates revenue primarily through the sale of its pharmaceutical products.

The current research profile is Turnaround Candidate, with strong market confirmation. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC6.5%Model input; read with the evidence status and period context.

Operating margin5.9%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years20.1%Model input; read with the evidence status and period context.

FCF margin18.6%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.